Pembrolizumab as consolidation strategy in patients with multiple myeloma: Results of the GEM-Pembresid clinical trial

Puig, N. (Noemí)|||/items/6ff3624a-2657-4823-b2a4-68b3f7b42ba2; Corchete-Sánchez, L.A. (Luis A.)|||/items/f1a8d365-20f0-469d-a620-b55be72eb8f9; Pérez-Morán, J. (José)|||/items/ad7ae590-dfde-44fc-9130-e219b4a96740; Dávila, J. (Julio)|||/items/a98c0b8a-b870-45e9-b3a8-247bc9ec7584; Paino, T. (Teresa)|||/items/6aa89228-ce13-42f3-9876-f78bc55e6f44; Rubia, J. (Javier) de la|||/items/685756d6-8eb3-4223-a37a-845076723414; Oriol, A. (Albert)|||/items/6b2a6860-c90e-4147-86b6-664e85f36400; Martín-Sánchez, J. (Jesús)|||/items/8c12891b-ed9f-4e30-914e-83f542607a03; Arriba, F. (Felipe) de|||/items/47ce8d3a-0cde-4695-9a83-14c297ffba09; Bladé, J. (Joan)|||/items/2e3393a4-11c5-4a58-8b64-52150839a266; Blanchard, M.J. (María Jesús)|||/items/a0c7898b-0d59-4946-9baa-2a53654ea973; Gonzalez-Calle, V. (Veronica)|||/items/a2b3aa81-dedb-4212-a595-89bdc9ad8def; García-Sanz, R. (Ramón)|||/items/a1eb0718-40a6-4c41-a26a-df95ea92f2b5; Paiva, B. (Bruno)|||/items/b2c3efc5-27e1-4425-b452-efba1522c1d5; Lahuerta, J.J. (Juan José)|||/items/fd31a0c2-8942-4d10-a5ef-df2037229340; San-Miguel, J.F. (Jesús F.)|||/items/114f598d-f226-4fa6-aa75-909241328543; Mateos, M.V. (María Victoria)|||/items/13d4d308-51d0-4808-8051-67042c4f3f61; Ocio, E.M. (Enrique M.)|||/items/2e2c579b-5c69-4327-bbef-0107e8ab4f2e

Pembrolizumab as consolidation strategy in patients with multiple myeloma: Results of the GEM-Pembresid clinical trial

PD1 expression in CD4+ and CD8+ T cells is increased after treatment in multiple myeloma patients with persistent disease. The GEM-Pembresid trial analyzed the efficacy and safety of pembrolizumab as consolidation in patients achieving at least very good partial response but with persistent measurab...

Descripción completa

Detalles Bibliográficos
Autores:	Puig, N. (Noemí)\|\|\|/items/6ff3624a-2657-4823-b2a4-68b3f7b42ba2, Corchete-Sánchez, L.A. (Luis A.)\|\|\|/items/f1a8d365-20f0-469d-a620-b55be72eb8f9, Pérez-Morán, J. (José)\|\|\|/items/ad7ae590-dfde-44fc-9130-e219b4a96740, Dávila, J. (Julio)\|\|\|/items/a98c0b8a-b870-45e9-b3a8-247bc9ec7584, Paino, T. (Teresa)\|\|\|/items/6aa89228-ce13-42f3-9876-f78bc55e6f44, Rubia, J. (Javier) de la\|\|\|/items/685756d6-8eb3-4223-a37a-845076723414, Oriol, A. (Albert)\|\|\|/items/6b2a6860-c90e-4147-86b6-664e85f36400, Martín-Sánchez, J. (Jesús)\|\|\|/items/8c12891b-ed9f-4e30-914e-83f542607a03, Arriba, F. (Felipe) de\|\|\|/items/47ce8d3a-0cde-4695-9a83-14c297ffba09, Bladé, J. (Joan)\|\|\|/items/2e3393a4-11c5-4a58-8b64-52150839a266, Blanchard, M.J. (María Jesús)\|\|\|/items/a0c7898b-0d59-4946-9baa-2a53654ea973, Gonzalez-Calle, V. (Veronica)\|\|\|/items/a2b3aa81-dedb-4212-a595-89bdc9ad8def, García-Sanz, R. (Ramón)\|\|\|/items/a1eb0718-40a6-4c41-a26a-df95ea92f2b5, Paiva, B. (Bruno)\|\|\|/items/b2c3efc5-27e1-4425-b452-efba1522c1d5, Lahuerta, J.J. (Juan José)\|\|\|/items/fd31a0c2-8942-4d10-a5ef-df2037229340, San-Miguel, J.F. (Jesús F.)\|\|\|/items/114f598d-f226-4fa6-aa75-909241328543, Mateos, M.V. (María Victoria)\|\|\|/items/13d4d308-51d0-4808-8051-67042c4f3f61, Ocio, E.M. (Enrique M.)\|\|\|/items/2e2c579b-5c69-4327-bbef-0107e8ab4f2e
Tipo de recurso:	artículo
Fecha de publicación:	2020
País:	España
Institución:	Universidad de Navarra
Repositorio:	Dadun. Depósito Académico Digital de la Universidad de Navarra
Idioma:	inglés
OAI Identifier:	oai:dadun.unav.edu:10171/67664
Acceso en línea:	https://hdl.handle.net/10171/67664
Access Level:	acceso abierto
Palabra clave:	Pembrolizumab Immunotherapy Myeloma Consolidation

id	ES_f2fddefd9aefeaa1f2fb329d62eeeb01
oai_identifier_str	oai:dadun.unav.edu:10171/67664
network_acronym_str	ES
network_name_str	España
repository_id_str
spelling	Pembrolizumab as consolidation strategy in patients with multiple myeloma: Results of the GEM-Pembresid clinical trialPuig, N. (Noemí)\|\|\|/items/6ff3624a-2657-4823-b2a4-68b3f7b42ba2Corchete-Sánchez, L.A. (Luis A.)\|\|\|/items/f1a8d365-20f0-469d-a620-b55be72eb8f9Pérez-Morán, J. (José)\|\|\|/items/ad7ae590-dfde-44fc-9130-e219b4a96740Dávila, J. (Julio)\|\|\|/items/a98c0b8a-b870-45e9-b3a8-247bc9ec7584Paino, T. (Teresa)\|\|\|/items/6aa89228-ce13-42f3-9876-f78bc55e6f44Rubia, J. (Javier) de la\|\|\|/items/685756d6-8eb3-4223-a37a-845076723414Oriol, A. (Albert)\|\|\|/items/6b2a6860-c90e-4147-86b6-664e85f36400Martín-Sánchez, J. (Jesús)\|\|\|/items/8c12891b-ed9f-4e30-914e-83f542607a03Arriba, F. (Felipe) de\|\|\|/items/47ce8d3a-0cde-4695-9a83-14c297ffba09Bladé, J. (Joan)\|\|\|/items/2e3393a4-11c5-4a58-8b64-52150839a266Blanchard, M.J. (María Jesús)\|\|\|/items/a0c7898b-0d59-4946-9baa-2a53654ea973Gonzalez-Calle, V. (Veronica)\|\|\|/items/a2b3aa81-dedb-4212-a595-89bdc9ad8defGarcía-Sanz, R. (Ramón)\|\|\|/items/a1eb0718-40a6-4c41-a26a-df95ea92f2b5Paiva, B. (Bruno)\|\|\|/items/b2c3efc5-27e1-4425-b452-efba1522c1d5Lahuerta, J.J. (Juan José)\|\|\|/items/fd31a0c2-8942-4d10-a5ef-df2037229340San-Miguel, J.F. (Jesús F.)\|\|\|/items/114f598d-f226-4fa6-aa75-909241328543Mateos, M.V. (María Victoria)\|\|\|/items/13d4d308-51d0-4808-8051-67042c4f3f61Ocio, E.M. (Enrique M.)\|\|\|/items/2e2c579b-5c69-4327-bbef-0107e8ab4f2ePembrolizumabImmunotherapyMyelomaConsolidationPD1 expression in CD4+ and CD8+ T cells is increased after treatment in multiple myeloma patients with persistent disease. The GEM-Pembresid trial analyzed the efficacy and safety of pembrolizumab as consolidation in patients achieving at least very good partial response but with persistent measurable disease after first- or second-line treatment. Moreover, the characteristics of the immune system were investigated to identify potential biomarkers of response to pembrolizumab. One out of the 17 evaluable patients showed a decrease in the amount of M-protein, although a potential late effect of high-dose melphalan could not be ruled out. Fourteen adverse events were considered related to pembrolizumab, two of which (G3 diarrhea and G2 pneumonitis) prompted treatment discontinuation and all resolving without sequelae. Interestingly, pembrolizumab induced a decrease in the percentage of NK cells at cycle 3, due to the reduction of the circulating and adaptive subsets (0.615 vs. 0.43, p = 0.007; 1.12 vs. 0.86, p = 0.02). In the early progressors, a significantly lower expression of PD1 in CD8+ effector memory T cells (MFI 1327 vs. 926, p = 0.03) was observed. In conclusion, pembrolizumab used as consolidation monotherapy shows an acceptable toxicity profile but did not improve responses in this MM patient population. The trial was registered at clinicaltrials.gov with identifier NCT02636010 and with EUDRACT number 2015-003359-23.MDPI AGDadun. Depósito Académico Digital Universidad de Navarra20232023-10-1820202020-01-0120202020-01-01journal articlehttp://purl.org/coar/resource_type/c_6501info:eu-repo/semantics/articleapplication/pdfhttps://hdl.handle.net/10171/67664reponame:Dadun. Depósito Académico Digital de la Universidad de Navarrainstname:Universidad de NavarraInglésengopen accesshttp://purl.org/coar/access_right/c_abf2info:eu-repo/semantics/openAccessoai:dadun.unav.edu:10171/676642026-06-21T12:47:57Z
dc.title.none.fl_str_mv	Pembrolizumab as consolidation strategy in patients with multiple myeloma: Results of the GEM-Pembresid clinical trial
title	Pembrolizumab as consolidation strategy in patients with multiple myeloma: Results of the GEM-Pembresid clinical trial
spellingShingle	Pembrolizumab as consolidation strategy in patients with multiple myeloma: Results of the GEM-Pembresid clinical trial Puig, N. (Noemí)\|\|\|/items/6ff3624a-2657-4823-b2a4-68b3f7b42ba2 Pembrolizumab Immunotherapy Myeloma Consolidation
title_short	Pembrolizumab as consolidation strategy in patients with multiple myeloma: Results of the GEM-Pembresid clinical trial
title_full	Pembrolizumab as consolidation strategy in patients with multiple myeloma: Results of the GEM-Pembresid clinical trial
title_fullStr	Pembrolizumab as consolidation strategy in patients with multiple myeloma: Results of the GEM-Pembresid clinical trial
title_full_unstemmed	Pembrolizumab as consolidation strategy in patients with multiple myeloma: Results of the GEM-Pembresid clinical trial
title_sort	Pembrolizumab as consolidation strategy in patients with multiple myeloma: Results of the GEM-Pembresid clinical trial
dc.creator.none.fl_str_mv	Puig, N. (Noemí)\|\|\|/items/6ff3624a-2657-4823-b2a4-68b3f7b42ba2 Corchete-Sánchez, L.A. (Luis A.)\|\|\|/items/f1a8d365-20f0-469d-a620-b55be72eb8f9 Pérez-Morán, J. (José)\|\|\|/items/ad7ae590-dfde-44fc-9130-e219b4a96740 Dávila, J. (Julio)\|\|\|/items/a98c0b8a-b870-45e9-b3a8-247bc9ec7584 Paino, T. (Teresa)\|\|\|/items/6aa89228-ce13-42f3-9876-f78bc55e6f44 Rubia, J. (Javier) de la\|\|\|/items/685756d6-8eb3-4223-a37a-845076723414 Oriol, A. (Albert)\|\|\|/items/6b2a6860-c90e-4147-86b6-664e85f36400 Martín-Sánchez, J. (Jesús)\|\|\|/items/8c12891b-ed9f-4e30-914e-83f542607a03 Arriba, F. (Felipe) de\|\|\|/items/47ce8d3a-0cde-4695-9a83-14c297ffba09 Bladé, J. (Joan)\|\|\|/items/2e3393a4-11c5-4a58-8b64-52150839a266 Blanchard, M.J. (María Jesús)\|\|\|/items/a0c7898b-0d59-4946-9baa-2a53654ea973 Gonzalez-Calle, V. (Veronica)\|\|\|/items/a2b3aa81-dedb-4212-a595-89bdc9ad8def García-Sanz, R. (Ramón)\|\|\|/items/a1eb0718-40a6-4c41-a26a-df95ea92f2b5 Paiva, B. (Bruno)\|\|\|/items/b2c3efc5-27e1-4425-b452-efba1522c1d5 Lahuerta, J.J. (Juan José)\|\|\|/items/fd31a0c2-8942-4d10-a5ef-df2037229340 San-Miguel, J.F. (Jesús F.)\|\|\|/items/114f598d-f226-4fa6-aa75-909241328543 Mateos, M.V. (María Victoria)\|\|\|/items/13d4d308-51d0-4808-8051-67042c4f3f61 Ocio, E.M. (Enrique M.)\|\|\|/items/2e2c579b-5c69-4327-bbef-0107e8ab4f2e
author	Puig, N. (Noemí)\|\|\|/items/6ff3624a-2657-4823-b2a4-68b3f7b42ba2
author_facet	Puig, N. (Noemí)\|\|\|/items/6ff3624a-2657-4823-b2a4-68b3f7b42ba2 Corchete-Sánchez, L.A. (Luis A.)\|\|\|/items/f1a8d365-20f0-469d-a620-b55be72eb8f9 Pérez-Morán, J. (José)\|\|\|/items/ad7ae590-dfde-44fc-9130-e219b4a96740 Dávila, J. (Julio)\|\|\|/items/a98c0b8a-b870-45e9-b3a8-247bc9ec7584 Paino, T. (Teresa)\|\|\|/items/6aa89228-ce13-42f3-9876-f78bc55e6f44 Rubia, J. (Javier) de la\|\|\|/items/685756d6-8eb3-4223-a37a-845076723414 Oriol, A. (Albert)\|\|\|/items/6b2a6860-c90e-4147-86b6-664e85f36400 Martín-Sánchez, J. (Jesús)\|\|\|/items/8c12891b-ed9f-4e30-914e-83f542607a03 Arriba, F. (Felipe) de\|\|\|/items/47ce8d3a-0cde-4695-9a83-14c297ffba09 Bladé, J. (Joan)\|\|\|/items/2e3393a4-11c5-4a58-8b64-52150839a266 Blanchard, M.J. (María Jesús)\|\|\|/items/a0c7898b-0d59-4946-9baa-2a53654ea973 Gonzalez-Calle, V. (Veronica)\|\|\|/items/a2b3aa81-dedb-4212-a595-89bdc9ad8def García-Sanz, R. (Ramón)\|\|\|/items/a1eb0718-40a6-4c41-a26a-df95ea92f2b5 Paiva, B. (Bruno)\|\|\|/items/b2c3efc5-27e1-4425-b452-efba1522c1d5 Lahuerta, J.J. (Juan José)\|\|\|/items/fd31a0c2-8942-4d10-a5ef-df2037229340 San-Miguel, J.F. (Jesús F.)\|\|\|/items/114f598d-f226-4fa6-aa75-909241328543 Mateos, M.V. (María Victoria)\|\|\|/items/13d4d308-51d0-4808-8051-67042c4f3f61 Ocio, E.M. (Enrique M.)\|\|\|/items/2e2c579b-5c69-4327-bbef-0107e8ab4f2e
author_role	author
author2	Corchete-Sánchez, L.A. (Luis A.)\|\|\|/items/f1a8d365-20f0-469d-a620-b55be72eb8f9 Pérez-Morán, J. (José)\|\|\|/items/ad7ae590-dfde-44fc-9130-e219b4a96740 Dávila, J. (Julio)\|\|\|/items/a98c0b8a-b870-45e9-b3a8-247bc9ec7584 Paino, T. (Teresa)\|\|\|/items/6aa89228-ce13-42f3-9876-f78bc55e6f44 Rubia, J. (Javier) de la\|\|\|/items/685756d6-8eb3-4223-a37a-845076723414 Oriol, A. (Albert)\|\|\|/items/6b2a6860-c90e-4147-86b6-664e85f36400 Martín-Sánchez, J. (Jesús)\|\|\|/items/8c12891b-ed9f-4e30-914e-83f542607a03 Arriba, F. (Felipe) de\|\|\|/items/47ce8d3a-0cde-4695-9a83-14c297ffba09 Bladé, J. (Joan)\|\|\|/items/2e3393a4-11c5-4a58-8b64-52150839a266 Blanchard, M.J. (María Jesús)\|\|\|/items/a0c7898b-0d59-4946-9baa-2a53654ea973 Gonzalez-Calle, V. (Veronica)\|\|\|/items/a2b3aa81-dedb-4212-a595-89bdc9ad8def García-Sanz, R. (Ramón)\|\|\|/items/a1eb0718-40a6-4c41-a26a-df95ea92f2b5 Paiva, B. (Bruno)\|\|\|/items/b2c3efc5-27e1-4425-b452-efba1522c1d5 Lahuerta, J.J. (Juan José)\|\|\|/items/fd31a0c2-8942-4d10-a5ef-df2037229340 San-Miguel, J.F. (Jesús F.)\|\|\|/items/114f598d-f226-4fa6-aa75-909241328543 Mateos, M.V. (María Victoria)\|\|\|/items/13d4d308-51d0-4808-8051-67042c4f3f61 Ocio, E.M. (Enrique M.)\|\|\|/items/2e2c579b-5c69-4327-bbef-0107e8ab4f2e
author2_role	author author author author author author author author author author author author author author author author author
dc.contributor.none.fl_str_mv	Dadun. Depósito Académico Digital Universidad de Navarra
dc.subject.none.fl_str_mv	Pembrolizumab Immunotherapy Myeloma Consolidation
topic	Pembrolizumab Immunotherapy Myeloma Consolidation
description	PD1 expression in CD4+ and CD8+ T cells is increased after treatment in multiple myeloma patients with persistent disease. The GEM-Pembresid trial analyzed the efficacy and safety of pembrolizumab as consolidation in patients achieving at least very good partial response but with persistent measurable disease after first- or second-line treatment. Moreover, the characteristics of the immune system were investigated to identify potential biomarkers of response to pembrolizumab. One out of the 17 evaluable patients showed a decrease in the amount of M-protein, although a potential late effect of high-dose melphalan could not be ruled out. Fourteen adverse events were considered related to pembrolizumab, two of which (G3 diarrhea and G2 pneumonitis) prompted treatment discontinuation and all resolving without sequelae. Interestingly, pembrolizumab induced a decrease in the percentage of NK cells at cycle 3, due to the reduction of the circulating and adaptive subsets (0.615 vs. 0.43, p = 0.007; 1.12 vs. 0.86, p = 0.02). In the early progressors, a significantly lower expression of PD1 in CD8+ effector memory T cells (MFI 1327 vs. 926, p = 0.03) was observed. In conclusion, pembrolizumab used as consolidation monotherapy shows an acceptable toxicity profile but did not improve responses in this MM patient population. The trial was registered at clinicaltrials.gov with identifier NCT02636010 and with EUDRACT number 2015-003359-23.
publishDate	2020
dc.date.none.fl_str_mv	2020 2020-01-01 2020 2020-01-01 2023 2023-10-18
dc.type.none.fl_str_mv	journal article http://purl.org/coar/resource_type/c_6501
dc.type.openaire.fl_str_mv	info:eu-repo/semantics/article
format	article
dc.identifier.none.fl_str_mv	https://hdl.handle.net/10171/67664
url	https://hdl.handle.net/10171/67664
dc.language.none.fl_str_mv	Inglés eng
language_invalid_str_mv	Inglés
language	eng
dc.rights.none.fl_str_mv	open access http://purl.org/coar/access_right/c_abf2
dc.rights.openaire.fl_str_mv	info:eu-repo/semantics/openAccess
rights_invalid_str_mv	open access http://purl.org/coar/access_right/c_abf2
eu_rights_str_mv	openAccess
dc.format.none.fl_str_mv	application/pdf
dc.publisher.none.fl_str_mv	MDPI AG
publisher.none.fl_str_mv	MDPI AG
dc.source.none.fl_str_mv	reponame:Dadun. Depósito Académico Digital de la Universidad de Navarra instname:Universidad de Navarra
instname_str	Universidad de Navarra
reponame_str	Dadun. Depósito Académico Digital de la Universidad de Navarra
collection	Dadun. Depósito Académico Digital de la Universidad de Navarra
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_	1869424333987774464
score	15,300724

Pembrolizumab as consolidation strategy in patients with multiple myeloma: Results of the GEM-Pembresid clinical trial

Similares en LA Referencia